Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 7 for:    "Hepatocellular carcinoma (fibrolamellar variant)"

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02159989
Recruitment Status : Recruiting
First Posted : June 10, 2014
Last Update Posted : July 16, 2019
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This phase I trial studies the side effects and best dose of sapanisertib and ziv-aflibercept in treating patients with solid tumors that have come back (recurrent) and have spread to another place in the body (metastatic) or cannot be removed by surgery (unresectable). Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ziv-aflibercept may stop the growth of solid tumors by blocking the growth of new blood vessels necessary for tumor growth. Giving sapanisertib with ziv-aflibercept may kill more tumor cells.

Condition or disease Intervention/treatment Phase
Advanced Malignant Solid Neoplasm Fibrolamellar Carcinoma Metastatic Malignant Solid Neoplasm Ovarian Carcinoma Pancreatic Neuroendocrine Tumor Recurrent Malignant Solid Neoplasm Refractory Malignant Solid Neoplasm Unresectable Solid Neoplasm Drug: Sapanisertib Biological: Ziv-Aflibercept Phase 1

Detailed Description:

PRIMARY OBJECTIVES:

I. To evaluate safety and tolerability, determine maximum tolerated dose (MTD) and recommend a phase II dose of the combination of MLN0128 (TAK-228) (sapanisertib) with ziv-aflibercept in patients with advanced cancers refractory to standard therapy.

SECONDARY OBJECTIVES:

I. To give early indication of efficacy by evaluation of tumor size. II. To evaluate v-akt murine thymoma viral oncogene homolog 1 (Akt)/mechanistic target of rapamycin (serine/threonine kinase) (mTOR) signaling and adaptive responses; testing phosphorylation levels of biomarkers such as, but not limited to, vascular endothelial growth factor (VEGF)1 and 2, AKT and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) following treatment with MLN0128 (TAK-228) and ziv-aflibercept in peripheral blood mononuclear cells (PBMCs) and biopsy samples during expansion cohort.

OUTLINE: This is a dose-escalation study.

Patients receive sapanisertib orally (PO) once daily (QD) on days 2-4, 9-11, 16-18, and 23-25 and ziv-aflibercept intravenously (IV) over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 weeks.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 69 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of MLN0128 (TAK-228) (NSC# 768435) in Combination With Ziv-Aflibercept (NSC# 724770) in Patients With Advanced Cancers
Actual Study Start Date : June 3, 2014
Estimated Primary Completion Date : December 31, 2020


Arm Intervention/treatment
Experimental: Treatment (sapanisertib, ziv-aflibercept)
Patients receive sapanisertib PO QD on days 2-4, 9-11, 16-18, and 23-25 and ziv-aflibercept IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Sapanisertib
Given PO
Other Names:
  • INK-128
  • INK128
  • MLN-0128
  • MLN0128
  • TAK-228

Biological: Ziv-Aflibercept
Given IV
Other Names:
  • AFLIBERCEPT
  • AVE0005
  • Eylea
  • vascular endothelial growth factor trap
  • VEGF Trap
  • VEGF Trap R1R2
  • VEGF-Trap
  • Zaltrap




Primary Outcome Measures :
  1. Maximum tolerated dose (MTD) [ Time Frame: 28 days ]
    Will be defined as the highest dose level at which no more than 1 of 6 evaluable patients has had a dose-limiting toxicity. Graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (CTCAE version 5.0 beginning April 1, 2018).

  2. Incidence of toxicity [ Time Frame: Up to 4 weeks after completion of study treatment ]
    Will be graded according to NCI CTCAE version 4.0 (CTCAE version 5.0 beginning April 1, 2018). Adverse experiences and laboratory results will be summarized by severity grade.


Secondary Outcome Measures :
  1. Tumor response [ Time Frame: Up to 4 weeks after completion of study treatment ]
    Will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

  2. Changes in tumor size [ Time Frame: Baseline to up to day 8 of cycle 1 ]
    For each patient, the percent change in tumor size from baseline to best response will be computed. Will construct a waterfall plot of these values. Will compute the Pearson correlation coefficient between the percent change between baseline and cycle 1 day 8 for blood flow and tumor size

  3. Changes in total expression of AKT, ribosomal protein S6 (S6), phosphatase and tensin homolog (PTEN), and CD31 [ Time Frame: Baseline to up to day 8 of cycle 1 ]
    Will be assessed by reverse phase protein array (expansion cohort). For each marker, changes from baseline to cycle 1 day 8 will be assessed using a paired t-test unless the data are clearly not normally distributed in which case the Wilcoxon signed rank test will be used.

  4. Changes in phosphorylated expression of AKT, S6, PTEN, and CD31 [ Time Frame: Baseline to up to day 8 of cycle 1 ]
    Will be assessed by reverse phase protein array (expansion cohort). For each marker, changes from baseline to cycle 1 day 8 will be assessed using a paired t-test unless the data are clearly not normally distributed in which case the Wilcoxon signed rank test will be used.

  5. Changes in total expression of AKT, pS6, PTEN, and CD31 [ Time Frame: Baseline to up to day 8 of cycle 1 ]
    Will be assessed by immunohistochemistry (expansion cohort). For each marker, changes from baseline to cycle 1 day 8 will be assessed using a paired t-test unless the data are clearly not normally distributed in which case the Wilcoxon signed rank test will be used.

  6. Changes in phosphorylated expression of AKT, pS6, PTEN, and CD31 [ Time Frame: Baseline to up to day 8 of cycle 1 ]
    Will be assessed by immunohistochemistry (expansion cohort). For each marker, changes from baseline to cycle 1 day 8 will be assessed using a paired t-test unless the data are clearly not normally distributed in which case the Wilcoxon signed rank test will be used.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with advanced or metastatic cancer that is refractory to standard therapy or relapsed after standard therapy; patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
  • Patients enrolled in the expansion cohort must have biopsiable disease; there will be preferential enrollment of patients with pancreatic neuroendocrine tumors or ovarian cancer during the dose expansion cohort
  • Patients must be >= 4 weeks beyond treatment of any chemotherapy, other investigational therapy, hormonal, biological, targeted agents or radiotherapy, and must have recovered to =< grade 1 toxicity or previous baseline for each toxicity; exception: patients may have received palliative low dose radiotherapy to the limbs 1-4 weeks before this therapy provided pelvis, sternum, scapulae, vertebrae, or skull were not included in the radiotherapy field
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 1
  • Life expectancy of greater than 3 months
  • Leukocytes >= 3,000/mcL
  • Absolute neutrophil count >= 1,500/mcL
  • Platelets >= 100,000/mcL
  • Hemoglobin >= 9 g/dL
  • Total bilirubin =< 1.5 x institutional upper limit of normal
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal
  • Creatinine =< 1.5 x institutional upper limit of normal OR creatinine clearance >= 60 mL/min for patients with creatinine levels above institutional normal
  • Fasting serum glucose =< 130 mg/dL
  • Fasting triglycerides =< 300 mg/dL
  • Glycosylated hemoglobin (HbA1c) < 7.0%
  • Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
  • Women of child-bearing potential MUST have a negative serum or urine pregnancy test within 7 days unless prior hysterectomy or menopause (defined as 12 consecutive months without menstrual activity); patients should not become pregnant or breastfeed while on this study; women of child-bearing potential must agree to use 1 highly effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the informed consent through 90 days (or longer, as mandated by local labeling [e.g.; United Surgical Partners International (USPI), Summary of Product Characteristics (SmPC), etc;]) after the last dose of study drug; or agree to practice true abstinence; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; male patients, even if surgically sterilized (i.e., status post-vasectomy), who:

    • Agree to practice highly effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug, or
    • Agree to completely abstain from heterosexual intercourse
  • Ability to understand and the willingness to sign a written informed consent document
  • Ability to swallow oral medications

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered to =< grade 1 adverse events due to agents administered more than 4 weeks earlier
  • Patients who are receiving any other investigational agents
  • Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) or ziv-aflibercept
  • Uncontrolled intercurrent illness including active infection
  • Pregnant women are excluded from this study because MLN0128 (TAK-228) and ziv-aflibercept are agents with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with MLN0128 (TAK-228) and ziv-aflibercept, breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228) and ziv-aflibercept; these potential risks may also apply to other agents used in this study
  • Patients with known human immunodeficiency virus infection are not to be enrolled in the study
  • History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days or manifestations of malabsorption due to prior gastrointestinal (GI) surgery or GI disease that may alter the absorption of MLN0128 (TAK-228)
  • New York Heart Association class III or greater congestive heart failure within last 6 months or uncontrolled hyperlipidemia (cholesterol > 300 mg/dl; triglyceride 2.5 X upper limit of normal [ULN] despite lipid lowering agent) within last 3 months
  • Uncontrolled diabetes (fasting serum glucose > 130 mg/dl) despite best medical management or poorly controlled diabetes mellitus defined as hemoglobin (Hb)A1c > 7%; subjects with a history of transient glucose intolerance due to corticosteroid administration are allowed in this study if all other inclusion/exclusion criteria are met
  • History of uncontrolled hypertension, defined as blood pressure > 150/95 mmHg, or systolic blood pressure > 180 mmHg when diastolic blood pressure < 90 mmHg, on at least 2 repeated determinations on separate days within 3 months prior to study enrollment
  • Urine protein should be screened by dipstick or urine analysis; for proteinuria > 1+ or urine protein: creatinine ratio > 1.0, 24-hour urine protein should be obtained and the level should be < 2000 mg for patient enrollment
  • Patients on anticoagulant therapy with unstable dose of warfarin and/or having an out-of- therapeutic range international normalized ratio (INR) (> 3) within the 4 weeks prior to drug administration
  • Evidence of clinically significant bleeding diathesis or underlying coagulopathy, non-healing wound
  • History of any of the following within the last 6 months prior to study entry:

    • Ischemic myocardial event, including angina requiring therapy and artery revascularization procedures
    • Ischemic cerebrovascular event, including transient ischemic attack (TIA) and artery revascularization procedures
    • Requirement for inotropic support (excluding digoxin) or serious (uncontrolled) cardiac arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation or ventricular tachycardia)
    • Placement of a pacemaker for control of rhythm
    • Pulmonary embolism
  • Significant active cardiovascular or pulmonary disease at the time of study entry, including:

    • Uncontrolled high blood pressure (i.e., systolic blood pressure > 150 mm Hg, diastolic blood pressure > 95 mm Hg)
    • Pulmonary hypertension
    • Uncontrolled asthma or oxygen (O2) saturation < 90% by pulse oximetry on room air
    • Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement
    • Medically significant (symptomatic) bradycardia
    • History of arrhythmia requiring an implantable cardiac defibrillator
  • Baseline prolongation of the rate-corrected QT interval (QTc) (e.g. repeated demonstration of QTc interval > 480 milliseconds, or history of congenital long QT syndrome, or torsades de pointes)
  • Psychiatric illness/social situations that would limit compliance with study requirements
  • Have initiated treatment with bisphosphonates less than 30 days prior to the first administration of MLN0128 (TAK-228); concurrent bisphosphonate use is only allowed if the bisphosphonate was initiated at least 30 days prior to the first administration of MLN0128 (TAK-228)
  • Patients who are taking proton pump inhibitor (PPI) within 7 days before receiving the first dose of study drug or who require treatment with PPIs throughout the trial or those who are taking H2 receptor antagonists within 24 hours of the first dose of study drug
  • Patients with known history of hepatitis B surface antigen-positive, or known history or suspected active hepatitis C infection are not to be enrolled in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02159989


Locations
Layout table for location information
United States, Texas
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Aung Naing    713-792-3245      
Principal Investigator: Aung Naing         
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Aung Naing M.D. Anderson Cancer Center

Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT02159989     History of Changes
Other Study ID Numbers: NCI-2014-01107
NCI-2014-01107 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2013-0665
9585 ( Other Identifier: M D Anderson Cancer Center )
9585 ( Other Identifier: CTEP )
P30CA016672 ( U.S. NIH Grant/Contract )
U01CA062461 ( U.S. NIH Grant/Contract )
UM1CA186688 ( U.S. NIH Grant/Contract )
First Posted: June 10, 2014    Key Record Dates
Last Update Posted: July 16, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Neoplasms
Neuroendocrine Tumors
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Adenoma, Islet Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Adenoma
Pancreatic Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endothelial Growth Factors
Growth Substances
Physiological Effects of Drugs